FAQ/Help |
Calendar |
Search |
Today's Posts |
08-16-2011, 10:07 AM | #1 | ||
|
|||
Member
|
FDA, Industry Reach Generic Drug Fee Agreement
The New York Times, Published August 16, 2011 U.S. regulators and generic drugmakers have reached a compromise agreement for a user-fee program that would require the companies to pay some $299 million in the first year to accelerate drug approvals. The Food and Drug Administration has been in negotiations with the generic drug industry since February to establish a user-fee program similar to one in place for brand-name drugs and medical devices. |
||
Reply With Quote |
"Thanks for this!" says: | VICTORIALOU (08-16-2011) |
08-17-2011, 01:38 PM | #2 | |||
|
||||
Member
|
Quote:
This arrangement probably makes perfectly good business sense, but the potential for serious conflict of interest seemed then, and still does to me, to be obvious. Now we find that the generic drug manufacturers will be ponying up for the same scam, and the cost will, as with the brand name drugs, be passed on the patients. What a world! Robert |
|||
Reply With Quote |
"Thanks for this!" says: | olsen (08-19-2011), VICTORIALOU (08-21-2011) |
08-18-2011, 10:12 AM | #3 | ||
|
|||
Senior Member
|
Quote:
|
||
Reply With Quote |
"Thanks for this!" says: | olsen (08-19-2011) |
08-19-2011, 07:16 AM | #4 | |||
|
||||
Senior Member
|
The Prescription Drug User Fee Act (PDUFA) was enacted in 1992 and renewed in 1997 (PDUFA II), 2002 (PDUFA III), and 2007 (PDUFA IV)
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
Reply With Quote |
"Thanks for this!" says: | RLSmi (08-22-2011) |
08-21-2011, 06:26 AM | #5 | |||
|
||||
Junior Member
|
Before the PDUFA was passed in 1992, the average wait time for the FDA to review a new drug application was 31.3 months. And this is after about 5 years of clinical trials.
It was in response to criticism from patients, physicians, and pharmaceutical companies about these lengthy delays in the FDA's new drug application reviews that prompted Congress to pass the PDUFA. Since passage of the Act, the average review time has decreased to 10 months for standard drugs (and 6 or less months for critical drugs). User fees now make up about 65% of the FDA's costs of reviewing new drug applications. The user fees aren't cheap. In 2008, a new drug application with clinical trial data was $1.2 million. Is this the best way to handle new drug reviews? Given our current economic climate, it is hard to image any change in the near (or even middling) future. Tremorgrrrl |
|||
Reply With Quote |
"Thanks for this!" says: | RLSmi (08-22-2011) |
08-21-2011, 07:57 AM | #6 | |||
|
||||
Junior Member
|
A final comment....
Canada also instituted user fees for its new drug application reviews two years after the United States passed PDUFA. The Canadian law, unlike the US law, replaced government money with user-fee generated revenues; in the US, the user-fee program is intended to supplement the FDA's appropriations. Moreover, Canada has a relatively opaque drug approval processes; with increased industry participation through user-fees, this is unlikely to change. In the US, by contrast, considerably more information about the drug approval process (and about specific new drug applications) is and has always been publicly-available. Such transparency (which accounts for yet another cost in the approval process) is an important counter-balance to keep actual and perceived biases in the approval process in check. Tremorgrrrl |
|||
Reply With Quote |
"Thanks for this!" says: | RLSmi (08-22-2011) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
How the drug industry distorts medicine and politics. | Parkinson's Disease | |||
FDA To Strengthen Generic Drug Program...Streamline Generic Drug Approval Process | Parkinson's Disease |